STOCK TITAN

Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Stevanato Group S.p.A. (NYSE: STVN) will release its financial results for the fourth quarter and year end of 2023 on March 7, 2024. A conference call and webcast will be held to discuss the results, with pre-registration available for immediate access.
Positive
  • None.
Negative
  • None.

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET).

Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 7, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: STVN conference call pre-registration.

Webcast: A live, listen-only webcast of the call will be available at the following link: STVN webcast.

Dial in: Those who are unable to pre-register may dial in by calling:

Italy: +39 02 802 09 11
United Kingdom: +44 1 212 818004
United States: +1 718 705 8796
United States Toll Free: +1 855 265 6958

Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=.

Replay:

The webcast will be archived for three months on the Company’s Investor Relations section of its website.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com.

Investor Relations

Lisa Miles

lisa.miles@stevanatogroup.com

Media

media@stevanatogroup.com

Source: Stevanato Group S.p.A.

FAQ

When will Stevanato Group S.p.A. (STVN) release its financial results for Q4 and year end 2023?

Stevanato Group S.p.A. (NYSE: STVN) will release its financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024.

How can participants pre-register for the conference call?

Participants can pre-register for the conference call using the following link: STVN conference call pre-registration.

Where can participants access the slide presentation during the conference call?

The slide presentation will be available on the morning of the call on the 'Financial Results' page under the Company's Investor Relations section of its website.

How long will the webcast be archived for?

The webcast will be archived for three months on the Company’s Investor Relations section of its website.

Stevanato Group S.p.A.

NYSE:STVN

STVN Rankings

STVN Latest News

STVN Stock Data

5.76B
41.66M
2.13%
77.59%
0.87%
Glass Container Manufacturing
Manufacturing
Link
United States of America
Piombino Dese

About STVN

founded in 1949, stevanato group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. it is comprised of two operational divisions: - pharmaceutical systems (ompi and balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. - engineering systems (spami, optrel, innoscan and svm brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. these two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that stevanato group has complete control over the entire production process, from purchasing the finest raw materials to offering exceptional after-sales customer service. the group also benefits from the sglab activ